Comparative Pharmacology
Head-to-head clinical analysis: DYCILL versus KLEBCIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYCILL versus KLEBCIL.
DYCILL vs KLEBCIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release parenteral formulation of penicillin G that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Klebcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250 mg orally every 6 hours or 500 mg orally every 12 hours.
KLEBCIL (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours infused over 2 hours.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 20 hours in severe cases).
2-3 hours (prolonged to 30-60 hours in severe renal impairment; adjust dosing)
Renal: approx. 60-80% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: minor (less than 10%).
Primarily renal (70-80% unchanged); minor biliary/fecal (15-20%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic